NCT03267381View on ClinicalTrials.gov

Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy

CompletedOBSERVATIONAL
Enrollment

37

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

September 27, 2023

Study Completion Date

September 27, 2023

Conditions
Melanoma
Interventions
OTHER

Blood draw (before surgery)

Blood will be drawn before surgery

OTHER

Blood draw (every 3 months)

Blood will be drawn every 3 months

OTHER

Blood draw (at diagnosis)

Blood will be drawn at time of diagnosis

Trial Locations (1)

37232

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

Wren Laboratories LLC

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT03267381 - Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy | Biotech Hunter | Biotech Hunter